The Cardiac Safety of Chloroquine Phosphate Treatment in Patients with Systemic Lupus Erythematosus: The Influence on Arrhythmia,Heart Rate Variability and Repolarization Parameters

Abstract

Antimalarials are used to treat cutaneous and systemic lupus erythematosus (SLE). Even though cardiac damage is a rare complication, over the last decade several reports have raised the issue of cardiotoxicity associated with antimalarials. Therefore, the aim of study was to evaluate the influence of seven-month chloroquine treatment with a 250 mg daily dose on arrhythmia, conduction disturbances as well as heart rate variability and repolarization parameters assessed in 24-hour Holter monitoring. The studied group included 28 SLE patients treated with chloroquine as a monotherapy. In all the patients standard 12 leads surface ECG (50 mm) and the 24-hour ECG Holter monitoring (Oxford Medilog Excel-2) were performed before and after chloroquine phosphate treatment. All subjects presented sinus rhythm both at the enrollment and after treatment. No episodes of paroxysmal arrhythmias or conduction disturbances were reported during the study. All the patients were characterized by tendency to tachycardia, but no significant differences in mean heart rate were found before and after chloroquine administration. Similarly, no changes in heart rate variability or repolarization parameters were observed.

Keywords

arrhythmias cardiac toxicity chloroquine treatment heart rate variability Holter monitoring repolarization systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Ritschel WA , Hammer GV , Thompson GA. Pharmakinetics of antimalarials and proposals for dosage regiments . Int J Clin Pharmacol Biopharm 1978; 16: 395-401 .

Laaksonem AL , Koskiahde V , Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus . Scad J Rheumatol 1974; 3: 103-108 .

McChesney EW , Rothfield NF. Comparative metabolic studies of chloroquine and hydroxychloroquine . Arthritis Rheum 1964; 7: 328-329 .

Wallace DJ. Antimalarials: the real advance in lupus . Lupus 2001; 10: 385-387 .

Baguet JP , Tremel F , Fabre M. Chloroquine cardiomyopathy with conduction disorders . Heart 1999; 81: 221-223 .

Cervera . Cardiac toxicity secondary to long term treatment with chloroquine . Am Rheum Dis 2001; 60: 301-302 .

Teixeira RA , Martinelli Filho M , Benvenuti LA et al. Cardiac damage from chronic use of chloroquine: a case report and review of the literature . Arq Bras Cardiol 2002; 79: 85-88 .

Nord JE , Shah PK , Rinaldi RZ , Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature . Semin Arthritis Rheum 2004; 33: 336-351 .

McAllister HA Jr , Ferrans VJ , Hall RJ , Strickman NE , Bossart MI. Chloroquine-induced cardiomyopathy . Arch Pathol Lab Med 1987; 111: 953-956 .

10.

Veinot JP , Ma KT , Zarychanski R. Chloroquine related toxicity . J Rheumatol 1998; 25: 1221-1225 .

11.

Freihage JH , Patel NC , Jacobs WR et al. Heart transplantation in patient with chloroquine-induced cardiomyopathy . J Heart Lung Transplant 2004; 23: 252-255 .

12.

Naqvi TZ , Luthringer D , Marchevsky A , Saouf R , Gul K , Buchbinder NA. Chloroquine-induced cardiomyopathy-echocardiographic features . J Am Soc Echocardiogr 2005; 18: 383-387 .

13.

Kang J , Chen XL , Wang L , Rampe D. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG . J Pharmacol Exp Ther 2001; 299: 290-296 .

14.

Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology . Circulation 1996; 93: 1043-1065 .

15.

Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1997; 40: 1725-1725 .

16.

Liang MH , Socher SA , Larson MG , Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1107-1118 .

17.

D’Cruz D , Khamashta M , Hughes G. Cardiovascular manifestations of systemic lupus erythematosus. In Wallace DJ , Hahn BH eds. Systemic lupus erythematosus. Lippincott Williams & Wilkins , 2002: 661-745.

18.

Landewe RB , Miltenburg AM , Breedveld FC et al. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis . J Rheumatol 1992; 19: 1353-1357 .

19.

Salmeron G , Lipsky PE. Immunosupressive potential of antimalarials . Am J Med 1983; 18: 19-24 .

20.

Sjolin-Forsberg G , Berne B , Eggelte TA et al. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients . Acta Derm Venereol 1995; 22: 221-225 .

21.

Olczyk K , Drozdz M , Kucharz E et al. Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus . Med Interne 1984; 22: 221-225 .

22.

Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development . Lupus 1996; 5: S4-S10 .

23.

Sperber K , Quraishi H , Kalb TH et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1) and IL-6 in humans monocytes and T cells . J Rheumatol 1993; 20: 803-808 .

24.

Yi AK , Peckham DW , Ashman RF , Krieg A. CpG DNA rescues B cells from apoptosis by activating NFkB and preventing mitochondrial membrane potential disruption via chloroquine-sensitive pathway . Int Immunol 1999; 11: 2015-2024 .

25.

Coban C , Ishii KJ , Kawai T et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin . JEM 2005; 201: 19-25 .

26.

Lenert P.

Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Clin Exp Immunol 2005; 140: 1-10 .

27.

Sjolin-Frsberg G , Berne B , Blixt C et al. Chloroquine phosphate: a long term follow up of drug concentration in skin suction blister fluid and plasma . Acta Derm Venereol 1993; 73: 426-429 .

28.

Reuss-Borst M , Berner B , Wulf G , Muller GA. Complete heart block as a rare complication of treatment with chloroquine . J Rheumatol 1999; 26: 1394-1395 .

29.

Comin-Colet J , Sanchez-Corral MA , Alegre-Sancho JJ et al. Complete Heart block in an adult with systemic lupus erythematosus and recent onset of hydroxychloroquine therapy . Lupus 2001; 10: 59-62 .

30.

Guedira N , Hajjaj-Hassouni N , Srairi JE , el Hassani S , Fellat R , Benomar M. Third-degree atrioventricular block in a patient under chloroquine theraphy . Rev Rhum Engl Ed 1998; 65: 58-62 .

31.

Harris L , Downar E , Shaikh NA , Chen T. Antiarrhythmic potential of chloroquine: new use for an old drug . Can J Cardiol 1988; 4: 295-300 .

32.

Touze JE , Heno L , Foucade JC et al.

The effect of antimalarial drugs on ventricular repolarization

Am J Trop Med Hyg 2002; 67: 54-60 .

33.

Looareesuwan S , White NJ , Chanthavanich P et al. Cardiovascular toxicity and distribution kinetics of intravenous chloroquine . Br J Clin Pharmacol 1986; 22: 31-36 .